Careers  |  Sign In  |  Register  |   Twitter

FDA Reports Concerns Over Multiple Sclerosis Drug

Bloomberg News reports that the FDA has issued a report on Sanofi‘s multiple sclerosis drug, Lemtrada, warning of its fatal symptoms. Lemtrada was approved earlier this year in Europe and “was at the center of Paris-based Sanofi’s $20 billion acquisition of Genzyme Corp. in 2011.” Its “serious and potentially fatal” outcomes include autoimmune and thyroid disease and even cancer. The FDA reports concerns that these side effects “may not be balanced by the uncertainty that exists in the limited evidence of the potential clinical benefits from clinical trials that were not well-controlled.”

Read the article published by Bloomberg News.

Read the FDA report.